Thermo Fisher Scientific Inc. (NYSE:TMO) Position Increased by Hudson Valley Investment Advisors Inc. ADV

Hudson Valley Investment Advisors Inc. ADV boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,331 shares of the medical research company’s stock after buying an additional 268 shares during the period. Thermo Fisher Scientific accounts for approximately 1.2% of Hudson Valley Investment Advisors Inc. ADV’s investment portfolio, making the stock its 26th largest holding. Hudson Valley Investment Advisors Inc. ADV’s holdings in Thermo Fisher Scientific were worth $10,577,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. Legacy Private Trust Co. lifted its position in Thermo Fisher Scientific by 1.8% in the 4th quarter. Legacy Private Trust Co. now owns 11,912 shares of the medical research company’s stock valued at $6,197,000 after purchasing an additional 205 shares during the last quarter. First Hawaiian Bank raised its holdings in shares of Thermo Fisher Scientific by 3.0% during the fourth quarter. First Hawaiian Bank now owns 4,158 shares of the medical research company’s stock valued at $2,163,000 after buying an additional 122 shares during the last quarter. Douglas Lane & Associates LLC grew its holdings in Thermo Fisher Scientific by 1.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company’s stock worth $94,948,000 after buying an additional 3,460 shares in the last quarter. Fulton Bank N.A. increased its position in Thermo Fisher Scientific by 3.7% in the 4th quarter. Fulton Bank N.A. now owns 8,161 shares of the medical research company’s stock valued at $4,246,000 after acquiring an additional 288 shares during the period. Finally, One Wealth Capital Management LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $835,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1 %

Shares of NYSE:TMO opened at $545.00 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company has a market cap of $208.46 billion, a PE ratio of 34.17, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76. The firm has a 50 day simple moving average of $530.21 and a 200 day simple moving average of $568.07.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $5.69 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on TMO. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Evercore ISI cut their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $650.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.